Microencapsulation of budesonide with dextran by spray drying technique for colon-targeted delivery: An in vitro/in vivo evaluation in induced colitis in rat

Journal of Microencapsulation

Volumn 28, Issue 1, 2011, Pages 62-73

  Varshosaz, Jaleh ^a   Ahmadi, Fatemeh ^a   Emami, Jaber ^a   Tavakoli, Naser ^a   Minaiyan, Mohsen ^a   Mahzouni, Parvin ^a   Dorkoosh, Farid ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Budesonide; Colon delivery; Dextran; Microencapsulation; Spray dying; Ulcerative colitis

Indexed keywords

ACETIC ACID; BUDESONIDE; DEXTRAN; MESALAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON INJURY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CRYPT; MALE; MICROENCAPSULATION; MOLECULAR WEIGHT; NONHUMAN; RAT; SCORING SYSTEM; SPRAY DRYING; SUSPENSION; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CALORIMETRY, DIFFERENTIAL SCANNING; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLITIS, ULCERATIVE; COLON; DESICCATION; DEXTRANS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; MALE; RATS; RATS, WISTAR; X-RAY DIFFRACTION;

EID: 78650500199     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2010.529947     Document Type: Article

References (31)

1. Aslan A, Temiz M, Atik E, Polat G, Sahinler N, Besirov E, Aban N, Parsak CK. Effectiveness of mesalamine and propolis in experimental colitis. Adv Ther, 2007;24(5):1085-97.
2. Bickston SJ, Cominelli F. Inflammatory bowel disease: Short- and long-term treatments. Dis Mon, 1998;44(4):141-72.
3. Billon A, Bataille B, Cassanas G, Jacob M. Development of spray-dried acetaminophen microparticles using experimental designs. Int J Pharm, 2000;203(1-2):159-68.
4. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest, 1993;69:238-49.
5. Cui N, Friend DR, Fedorak RN. A budesonide prodrug accelerates treatment of colitis in rats. Gut, 1994;35(10):1439-46.
6. Dieleman LA, Palmen MJHJ, Akol H, Bloemena E, Peña AS, Meuwissen SGM, Van Rees EP. Chronic experimental colitis induced by dextransulfate sodium (DSS) is characterized by Th1 and Th2 cyto-kines. Clin Exp Immunol, 1998;114:385-91.
7. Edsbacker S, Andersson T, McKeage K, Goa KL. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet, 2004;43(12):803-21.
8. Edsbacker S, Larsson P, Wollmer P. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. Eur J Gastroenterol Hepatol, 2002;14:1357-62.
9. Ei-Arini SK, Leuenberger H. Modelling of drug release from polymer matrices: Effect of drug loading. Int J Pharm, 1995;121(2):141-8.
10. El Medany A, Mahgoub A, Mustafa A, Arafa M, Morsi M. The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. Eur J Pharmacol, 2005;507:291-9.
11. Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Delev Rev, 2005;57(2):303-16.
12. Friend DR. Issues in oral administration of locally acting glucocorticoster-oids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther, 1998;12(7):591-603.
13. Gohel MC, Panchal MK. Novel use of similarity factors and Sd for the development of diltiazem HCl modified-release tablets using a 32 factorial design. Drug Dev Ind Pharm, 2002;28(1):77-87.
14. Gorgulu S, Yagci G, Kaymakcioglu N, Ozkara M, Kurt B, Ozcan A, Kaya O, Sadir S, Tufan T. Hyperbaric oxygen enhances the efficiency of 5-ami-nosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci, 2006;51(3):480-7.
15. He P, Davis SS, Illum L. Chitosan microspheres prepared by spray drying. Int J Pharm, 1999;187:53-65.
16. Knigge KL. Inflammatory bowel disease. Clin Cornerstone, 2002;4(4):49-57.
17. Lee JS, Jung YJ, Doh MJ, Kim YM. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev Ind Pharm, 2001;27(4):331-6.
18. McLeod AD, Friend DR, Tozer TN. Synthesis and chemical stability of glucocorticoid-dextran esters: Potential prodrugs for colon-specific delivery. Int J Pharm, 1993;92(1-3):105-14.
19. Moretti MDL, Gavini E, Juliano C, Pirisino G, Giunchedi P. Spray-dried microspheres containing ketoprofen formulated into capsules and tablets. J Microencapsul, 2001;18(1):111-21.
20. Paiva LAF, Gurgel LA, De Sousa ET, Silveira ER, Silva RM, Santos FA, Rao VSN. Protective effect of Copaifera langsdorffii oleo-resin against acetic acid-induced colitis in rats. J Ethnopharmacol, 2004;93(1):51-6.
21. Palmieri GF, Wehrlëi P, Stamm A. Evaluation of spray drying as a method to prepare microcapsules for controlled drug release. Drug Dev Ind Pharm, 1994;20:2859-79.
22. Rama Prasad YV, Krishnaiah YSR, Satyanarayana S. In vitro evaluation of guar gum as a carrier for colon-specific drug delivery. J Control Release, 1998;51:281-7.
23. Rodriguez M, Antunez JA, Taboada C, Seijo B, Torres D. Colon-specific delivery of budesonide from microencapsulated cellulosic cores: Evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol, 2001;53(9):1207-15.
24. Shyale S, Chowdhary KPR, Krishnaiah YSR. Development of colon-targeted albendazole-b-cyclodextrin-complex drug delivery systems. Drug Dev Res, 2005;65:76-83.
25. Swaminath A, Kornbluth A. Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep, 2007;9(6):513-20.
26. Tozaki H, Fujita T, Komoike J, Kim SI, Terashima H, Muranishi S, Okabe S, Yamamoto A. Colon-specific delivery of budesonide with azopolymer-coated pellets: Therapeutic effects of budesonide with a novel dosage form against 2, 4, 6-trinitrobenzenesulphonic acid-induced colitis in rats. J Pharm Pharmacol, 1999;51(3):257-61.
27. Varshosaz J, Emami J, Ahmadi F, Tavakoli N, Minaiyan M, Fassihi A, Mahzouni P, Dorkoosh F. Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: In vitro/in vivo evaluation in induced ulcerative colitis. J Drug Target, 2010a; Posted online on April 30 (Epub ahead of print).
28. Varshosaz J, Emami J, Fassihi A, Tavakoli N, Minaiyan M, Ahmadi F, Mahzouni P, Dorkoosh F. Effectiveness of budesonide-succinate-dex-tran conjugate as a novel prodrug of budesonide against acetic acid-induced colitis in rats. Int J Colorectal Dis, 2010b;25(10):1159-65.
29. Varshosaz J, Emami J, Tavakoli N, Fassihi A, Minaiyan M, Ahmadi F, Dorkoosh F. Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int J Pharm, 2009;365:69-76.
30. Wan LS, Heng PWS, Chia CGH. Spray drying as a process for microen-capsulation and the effect of different coating polymers. Drug Dev Ind Pharm, 1992;18:997-1011.
31. Williams KL, Randall Fuller C, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK. Enhanced survival and muco-sal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterol, 2001; 120(4):925-37.